Alfageme Inmaculada, de Lucas Pilar, Ancochea Julio, Miravitlles Marc, Soler-Cataluña Juan José, García-Río Francisco, Casanova Ciro, Rodríguez González-Moro José Miguel, Cosío Borja G, Sánchez Guadalupe, Soriano Joan B
Unidad de Gestión Clínica de Neumología, Hospital Universitario Virgen de Valme, Departamento de Medicina, Universidad de Sevilla, Sevilla, España.
Servicio de Neumología, Hospital General Gregorio Marańon, Madrid, España.
Arch Bronconeumol (Engl Ed). 2019 Jan;55(1):38-47. doi: 10.1016/j.arbres.2018.05.011. Epub 2018 Jul 7.
The EPISCAN study, published in 2007, was an update of the results of the 1997 IBERPOC study. Changes in demographics and exposure to risk factors demand the periodic update of prevalence and determining factors in COPD. This article is a summary of the protocol and tools used in EPISCAN II.
The primary objective of EPISCAN II is to estimate the prevalence of COPD among the general population aged 40 years or more in the 17 autonomous communities of Spain. The sample size requires 600 participants (300 men and 300 women) per center, selected by screening 10,200 participants in a short visit (questionnaire plus forced post-bronchodilator spirometry). Of these, 800 (400 with COPD and 400 without COPD) will also perform a long visit (including a walking test, blood tests, determination of diffusion, pulse oximetry and bioimpedance, and low radiation CT).
The first participant was recruited on 28 February 2017. As of 22 November 2017, a total of 3,581 participants had been included, of whom 422 had already performed the long visit. It is estimated that the field work will be completed by December 2018. The new imaging data, biomarkers, and information on new exposures, such as electronic cigarettes and environmental pollution, will help us re-quantify the burden of COPD.
EPISCAN II will provide updated information on prevalence and determinants of COPD in Spain, allowing for the comparison of spirometric results and other factors associated with COPD among the 17 autonomous communities.
2007年发表的EPISCAN研究是1997年IBERPOC研究结果的更新。人口统计学和危险因素暴露的变化要求定期更新慢性阻塞性肺疾病（COPD）的患病率及其决定因素。本文是EPISCAN II中使用的方案和工具的总结。
EPISCAN II的主要目标是估计西班牙17个自治区40岁及以上普通人群中COPD的患病率。样本量要求每个中心有600名参与者（300名男性和300名女性），通过在短时间就诊时（问卷调查加支气管扩张剂后用力肺活量测定）筛选10200名参与者来选取。其中，800人（400名COPD患者和400名非COPD患者）还将进行长时间就诊（包括步行试验、血液检查、弥散测定、脉搏血氧饱和度测定和生物电阻抗测定，以及低剂量辐射CT）。
第一名参与者于2017年2月28日招募。截至2017年11月22日，共纳入3581名参与者，其中422人已经完成了长时间就诊。预计实地工作将于2018年12月完成。新的影像数据、生物标志物以及关于新暴露因素（如电子烟和环境污染）的信息将帮助我们重新量化COPD的负担。
EPISCAN II将提供西班牙COPD患病率及其决定因素的最新信息，以便比较17个自治区之间的肺活量测定结果以及与COPD相关的其他因素。
